Screener
AnaptysBio, Inc. ANAB Noncash Advance Future Royalties Interest Expense
Noncash Advance Future Royalties Interest Expense at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by AnaptysBio, Inc. in its filing.
Tagged under the XBRL concept anab:NoncashAdvanceFutureRoyaltiesInterestExpense.
The source filing: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:20 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219515
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Loss from operations | (34,637) | (27,539) |
| Other income (expense), net: | ||
| Interest income | 2,653 | 4,413 |
| Non-cash interest expense for the sale of future royalties | (20,859) | (18,061) |
| Other (expense) income, net | (1) | 1,902 |
| Total other expense, net | (18,207) | (11,746) |
| Loss before income taxes | (52,844) | (39,285) |
| Provision for income taxes | (40) | (44) |
Item 1. Consolidated Financial Statements
FAQ
- What is AnaptysBio, Inc.'s noncash advance future royalties interest expense?
- AnaptysBio, Inc. (ANAB) reported noncash advance future royalties interest expense of $20.86M in Q1 2026.
- How has AnaptysBio, Inc.'s noncash advance future royalties interest expense changed year-over-year?
- AnaptysBio, Inc.'s noncash advance future royalties interest expense increased by 15.5% year-over-year, from $18.06M to $20.86M.
- What is the long-term trend for AnaptysBio, Inc.'s noncash advance future royalties interest expense?
- Over 4 years (2021 to 2025), AnaptysBio, Inc.'s noncash advance future royalties interest expense has grown at a 172.4% compound annual growth rate (CAGR), from $1.45M to $79.89M.
- What does noncash advance future royalties interest expense mean?
- This represents the non-cash interest expense associated with financing arrangements where the company receives upfront capital in exchange for future royalty payments. It reflects the cost of alternative financing structures used to fund operations without immediate equity dilution. Investors should track this to understand the impact of debt-like obligations on long-term profitability and cash flow commitments.
Ask your AI about AnaptysBio, Inc.'s noncash advance future royalties interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude